Postoperative Levonorgestrel-Releasing Intrauterine System for Pelvic Endometriosis-Related Pain: A Randomized Controlled Trial
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To estimate the effectiveness of a postoperative levonorgestrel-releasing intrauterine system for relieving pelvic pain in patients with endometriosis. METHODS: A double-blind randomized controlled trial was conducted in 55 patients with endometriosis and moderate-to-severe dysmenorrhea (visual analog scale, greater than 50 mm) undergoing laparoscopic conservative surgery. After surgery, patients were randomized to a levonorgestrel-releasing intrauterine system (n=28) or expectant management (n=27) group. Primary outcome was the change of dysmenorrhea visual analog scale. Secondary outcomes included changes of pelvic pain and dyspareunia visual analog scale, Short Form-36 score, and adverse effects. RESULTS: The two groups were comparable in age, body mass index, parity, and baseline pain scores. At 12 months, the levonorgestrel-releasing intrauterine system group had a significantly lower median value of dysmenorrhea and noncyclic pelvic pain score. Compared with the control group, the levonorgestrel-releasing intrauterine system group had greater reduction in dysmenorrhea visual analog scale (-81.0 compared with -50.0 mm, P=.006) and pelvic pain visual analog scale (-48.5 compared with -22.0 mm, P=.038) but a comparable reduction in dyspareunia visual analog scale (-15.0 compared with -19.0 mm, P=.831). Two patients in levonorgestrel-releasing intrauterine system group (7.4%) and nine in the expectant management group (39.1%) had recurrent dysmenorrhea within 1 year postoperatively (P=.014). Number-needed-to-treat to prevent one case with recurrent dysmenorrhea within the first year was three cases. The Short Form-36 scores improved in the levonorgestrel-releasing intrauterine system group but did not change in the expectant management group. There was no serious adverse event during the study period. CONCLUSION: The levonorgestrel-releasing intrauterine system is effective and well accepted for long-term therapy after conservative surgery for patients with moderate to severe pain related to endometriosis. It can improve the patient's quality of life, including physical and mental health.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In fact, LNG-IUS use after surgery was associated with a significantly lower dysmenorrhea recurrence rate compared to with expectant management [231–233].”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [233]
In the citing paper
“These outcomes are superimposable to those obtained by Tanmahasamut et al. [83], that did not identify any endometrioma recurrence after 12 months of Accepted Manuscript treatment with LNG-IUS.”
From Oral and depot progestin therapy for endometriosis: towards a personalized medicine (2017) · cites this paper as [83]
In the citing paper
“Progestins were positively associated with HRQoL in women with endometriosis [20,21,23-25,27,29,30].”
From Health-related quality of life in women with endometriosis: a systematic review (2012) · cites this paper as [30]
In the citing paper
“Postoperative levonorgestrel intrauterine system (LNG-IUS) for 12 months improved both physical and mental health for women with moderate to severe pain related to endometriosis [30], although inconsistent finding was reported, possibly due to low sensitivity of the PGWBI questionnaire applied [23].”
From Health-related quality of life in women with endometriosis: a systematic review (2012) · cites this paper as [30]
Citations
Cites
Petta, C. A., Ferriani, R. A., Abrao, M. S., Hassan, D., Rosa e Silva, J. C., Podgaec, S., & Bahamondes, L. (2005) · Human Reproduction · doi:10.1093/humrep/deh869 · Cited by 363
Probability plotting methods for the analysis for the analysis of data
WILK, M. B., & GNANADESIKAN, R. (1968) · Biometrika · doi:10.1093/biomet/55.1.1 · Cited by 278
Treatment of severe postmenopausal endometriosis with an aromatase inhibitor
Takayama, K., Zeitoun, K., Gunby, R. T., Sasano, H., Carr, B. R., & Bulun, S. E. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00022-3 · Cited by 270
Vercellini, P., Frontino, G., De Giorgi, O., Aimi, G., Zaina, B., & Crosignani, P. G. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00608-3 · Cited by 263
Sutton, C. J. G., Pooley, A. S., Ewen, S. P., & Haines, P. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)00403-2 · Cited by 250
Ailawadi, R. K., Jobanputra, S., Kataria, M., Gurates, B., & Bulun, S. E. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.09.029 · Cited by 236
Levonorgestrel-Releasing Intrauterine Device
Luukkainen, T., Lähteenmäki, P., & Toivonen, J. (1990) · Annals of Medicine · doi:10.3109/07853899009147248 · Cited by 207
Vercellini, P., Aimi, G., Panazza, S., De Giorgi, O., Pesole, A., & Crosignani, P. G. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00291-5 · Cited by 169
Lockhat, F. B., Emembolu, J. O., & Konje, J. C. (2005) · Human Reproduction · doi:10.1093/humrep/deh650 · Cited by 166
Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis
Hornstein, M. D., Hemmings, R., Yuzpe, A. A., & Heinrichs, W. L. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)00360-9 · Cited by 155
Research works printed but not linked: 5
- Lin, 2001, J Formos Med Assoc, 100, 466
- Du, 1999, Zhonghua Fu Chan Ke Za Zhi, 34, 363
- Luciano, 1988, Obstet Gynecol, 72, 323
- Wilk, 1968, Biometrika, 55, 1
- Marques, 2004, J Reprod Med, 49, 115
Cited by
ESHRE guideline: endometriosis
Becker, C. M., Bokor, A., Heikinheimo, O., Horne, A., Jansen, F., Kiesel, L., King, K., Kvaskoff, M., Nap, A., Petersen, K., et al. (2022) · Human Reproduction Open · doi:10.1093/hropen/hoac009 · Cited by 1,712
“Women may be offered postoperative hormone treat-ment to improve the immediate outcome of surgery for pain in women with endometriosis if not desiring immediate pregnancy (Tanmahasamut et al. , 2012; Chen et al. , 2020).”
Rethinking mechanisms, diagnosis and management of endometriosis
Chapron, C., Marcellin, L., Borghese, B., & Santulli, P. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0245-z · Cited by 1,084
Systematic review of endometriosis pain assessment: how to choose a scale?
Bourdel, N., Alves, J., Pickering, G., Ramilo, I., Roman, H., & Canis, M. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmu046 · Cited by 372
RETIRED: No. 345-Primary Dysmenorrhea Consensus Guideline
Burnett, M., & Lemyre, M. (2017) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2016.12.023 · Cited by 332
Hormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
Zakhari, A., Delpero, E., McKeown, S., Tomlinson, G., Bougie, O., & Murji, A. (2021) · Human Reproduction Update · doi:10.1093/humupd/dmaa033 · Cited by 223
“Subgroup analysis on patients treated with CHC and LNG-IUS as well as sensitivity analyses limited to RCTs and high-quality studies showed a consistent decreased risk of endometriosis recurrence.”
BackgroundInfluentialEstrogen-progestins and progestins for the management of endometriosis
Vercellini, P., Buggio, L., Berlanda, N., Barbara, G., Somigliana, E., & Bosari, S. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.10.022 · Cited by 243
Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods
Bahamondes, L., Valeria Bahamondes, M., & Shulman, L. P. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv023 · Cited by 193
“The results showed that both the LNG-IUS and GnRH-a reduced pain scores according to the visual analogue scale without significant differences between both groups, although amenorrhoea occurred more rapidly among the GnRH users than the LNG-IUS users.”
BackgroundResultInfluentialMedical treatment of endometriosis-related pain
Vercellini, P., Buggio, L., Frattaruolo, M. P., Borghi, A., Dridi, D., & Somigliana, E. (2018) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2018.01.015 · Cited by 188
Endometriosis: where are we and where are we going?
Greene, A. D., Lang, S. A., Kendziorski, J. A., Sroga-Rios, J. M., Herzog, T. J., & Burns, K. A. (2016) · Reproduction · doi:10.1530/rep-16-0052 · Cited by 187
Prevention of the recurrence of symptom and lesions after conservative surgery for endometriosis
Koga, K., Takamura, M., Fujii, T., & Osuga, Y. (2015) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.08.026 · Cited by 158
“Regarding dyspareunia, there is no evidence of a positive effect of postoperative medical treatment, as neither cyclic or continuous OC regimens reduced the prevalence of symptoms (19, 20), as was also the case with LNG-IUS (27).”
BackgroundSystematic review of quality of life measures in patients with endometriosis
Bourdel, N., Chauvet, P., Billone, V., Douridas, G., Fauconnier, A., Gerbaud, L., & Canis, M. (2019) · PLOS ONE · doi:10.1371/journal.pone.0208464 · Cited by 135
Gibbons, T., Georgiou, E. X., Cheong, Y. C., & WISE, M. R. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005072.pub4 · Cited by 147
Health-related quality of life in women with endometriosis: a systematic review
Jia, S.-Z., Leng, J.-H., Shi, J.-H., Sun, P.-R., & Lang, J.-H. (2012) · Journal of Ovarian Research · doi:10.1186/1757-2215-5-29 · Cited by 132
“Postoperative levonorgestrel intrauterine system (LNG-IUS) for 12 months improved both physical and mental health for women with moderate to severe pain related to endometriosis [30], although inconsistent finding was reported, possibly due to low sensitivity of the PGWBI questionnaire applied [23].”
BackgroundTreatment of pain associated with deep endometriosis: alternatives and evidence
Ferrero, S., Alessandri, F., Racca, A., & Maggiore, U. L. R. (2015) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.08.031 · Cited by 147
Hormonal contraception in women with endometriosis: a systematic review
Grandi, G., Barra, F., Ferrero, S., Sileo, F. G., Bertucci, E., Napolitano, A., & Facchinetti, F. (2019) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2018.1550576 · Cited by 146
“A patient questionnaire showed marked improvement with both treatments in QoL and health-related satisfaction scores compared with preoperative values; no significant differences were found between the groups.”
BackgroundInfluentialAbou-Setta, A. M., Houston, B., Al-Inany, H. G., & Farquhar, C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005072.pub3 · Cited by 69
An update on the pharmacological management of endometriosis
Streuli, I., de Ziegler, D., Santulli, P., Marcellin, L., Borghese, B., Batteux, F., & Chapron, C. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.767334 · Cited by 104
“The Cochrane review also showed that there is no evidence that DMPA is more effective than other hormonal treatments such as the OCP or GNRH analogues for reducing pain symptoms.”
BackgroundInfluentialCharatsi, D., Koukoura, O., Ntavela, I. G., Chintziou, F., Gkorila, G., Tsagkoulis, M., Mikos, T., Pistofidis, G., Hajiioannou, J., & Daponte, A. (2018) · Advances in Medicine · doi:10.1155/2018/3461209 · Cited by 99
“Moreover, evidence suggests a beneficial effect of a levonorgestrel-releasing IUD on the prevention of dysmenorrhea, which may facilitate women’s long-term adherence to the treatment [55, 61].”
BackgroundVariation in outcome reporting in endometriosis trials: a systematic review
Hirsch, M., Duffy, J. M., Kusznir, J. O., Davis, C., Plana, N., Khan, K. S., Duffy, J. M. N., Farquhar, C. M., Hirsch, M., Johnson, N., et al. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.12.039 · Cited by 108
Barra, F., Scala, C., & Ferrero, S. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1461840 · Cited by 100
“Tanmahasamut [115] 55 women with confirmed endometriosis, postsurgical treatment LNG-IUD or expectant management 12 months In the LNG-IUD group there was a greater reduction in dysmenorrhea (p = 0.”
BackgroundArcoverde, F. V. L., Andres, M. D. P., Borrelli, G. M., Barbosa, P. D. A., Abrão, M. S., & Kho, R. M. (2019) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2018.09.774 · Cited by 76
Safety of medical treatments for endometriosis
Berlanda, N., Somigliana, E., Viganò, P., & Vercellini, P. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1121991 · Cited by 78
Yong, P. J. (2017) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.06.005 · Cited by 68
Chen, Y.-J., Hsu, T.-F., Huang, B.-S., Tsai, H.-W., Chang, Y.-H., & Wang, P.-H. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.02.008 · Cited by 64
ZANELOTTI, A., & DECHERNEY, A. H. (2017) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000291 · Cited by 57
Role of medical therapy in the management of deep rectovaginal endometriosis
Vercellini, P., Buggio, L., & Somigliana, E. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.08.038 · Cited by 62
Somigliana, E., Vercellini, P., Viganò, P., Benaglia, L., Busnelli, A., & Fedele, L. (2013) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2013.10.007 · Cited by 65
“Tanmahasamut et al [35], 2012 RCT LNG-IUD/EM 17/19 12 Median VAS score”
BackgroundInfluentialYoost, J. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s45710 · Cited by 65
“71 In one study randomizing women to either LNG-20 IUD or GnRHa, both treatments were found to be effective in controlling pelvic pain at 6 months, 69 however, those randomized to LNG-20 IUD had a continuation rate of 59% at 36 months, and 82% of these women reported a lower pain score compared to…”
Oral and depot progestin therapy for endometriosis: towards a personalized medicine
Buggio, L., Somigliana, E., Barbara, G., Frattaruolo, M. P., & Vercellini, P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1381086 · Cited by 58
“[83], that did not identify any endometrioma recurrence after 12 months of D ow nl oa de d by [ U ni ve rs ità d eg li St ud i d i M ila no ] at 0 9: 43 1 5 Se pt em be r 20 17”
BackgroundPartners in Crime: NGF and BDNF in Visceral Dysfunction
Coelho, A., Oliveira, R., Antunes‐Lopes, T., & Cruz, C. D. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190617095844 · Cited by 52
Drug delivery for the treatment of endometriosis and uterine fibroids
Friend, D. R. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0423-2 · Cited by 49
Fraser, I. S. (2012) · Contraception · doi:10.1016/j.contraception.2012.08.039 · Cited by 47
Sanghera, S., Barton, P. M., Bhattacharya, S., Horne, A. W., & Roberts, T. E. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010580 · Cited by 50
Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases
Kim, M., & Seong, S. J. (2013) · Obstetrics & Gynecology Science · doi:10.5468/ogs.2013.56.2.67 · Cited by 50
Use of Levonorgestrel Intrauterine System for Medical Indications in Adolescents
Bayer, L. L., & Hillard, P. J. A. (2013) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2012.09.022 · Cited by 45
“Specifically, compared with treatment with GnRH analogue [58] or depot medroxyprogesterone acetate (DMPA) [59], LNG-IUS showed comparable effectiveness and demonstrated superior effectiveness over expectant management [60,61].”
BackgroundD’Alterio, M. N., Saponara, S., Agus, M., Laganà, A. S., Noventa, M., Loi, E. S., Féki, A., & Angioni, S. L. (2021) · Gynecological Surgery · doi:10.1186/s10397-021-01096-5 · Cited by 50
“Tanmahasamut et al. 2012 [59] Double-blind randomized controlled trial 54 n = 28 Levonorgestrelreleasing intrauterine system n = 26 Control group Postoperative Levonorgestrelreleasing intrauterine system Not specified The Short Form-36 scores improved in the levonorgestrelreleasing intrauterine…”
BackgroundNovel drug delivery methods for improving efficacy of endometriosis treatments
Garzon, S., Laganà, A. S., Barra, F., Casarin, J., Cromi, A., Raffaelli, R., Uccella, S., Franchi, M. P., Ghezzi, F., & Ferrero, S. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1829589 · Cited by 46
“mas, although the small sample size and the short follow-up do not allow achieving definitive conclusions [76,78].”
BackgroundCho, S., Jung, J. A., Lee, Y., Kim, H. Y., Seo, S. K., Choi, Y. S., Lee, J. S., & Lee, B. S. (2014) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/aogs.12294 · Cited by 39
“Postoperative LNG-IUS insertion significantly reduced recurrent endometriosis-related pelvic pain (11,13,16).”
BackgroundEmerging therapy for endometriosis
Lindsay, S. F., Luciano, D. E., & Luciano, A. A. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1051966 · Cited by 46
“LNG-IUS administers 20 mcg per day of levonorgestrel locally over 5 years, and is typically better tolerated than systemic progestins [21].”
BackgroundInfluentialAdvances in pharmacotherapy for treating endometriosis
Tafi, E., Leone Roberti Maggiore, U., Alessandri, F., Bogliolo, S., Gardella, B., Vellone, V. G., Grillo, F., Mastracci, L., & Ferrero, S. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1085510 · Cited by 36
Lee, K. H., Jung, Y. W., Song, S. Y., Kang, B. H., Yang, J. B., Ko, Y. B., Lee, M., Han, H. Y., & Yoo, H. J. (2018) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/jog.13703 · Cited by 37
“tive pain relief and recurrence prevention in women recently submitted to surgery for endometriosis.(4,5)”
BackgroundIntrauterine Device Use in Adolescents With Disabilities
Schwartz, B. I., Alexander, M., & Breech, L. L. (2020) · PEDIATRICS · doi:10.1542/peds.2020-0016 · Cited by 37
Management of endometriosis: Toward value-based, cost-effective, affordable care
Vercellini, P., Facchin, F., Buggio, L., Barbara, G., Berlanda, N., Frattaruolo, M. P., & Somigliana, E. (2018) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2017.07.011 · Cited by 36
“The use of a levonorgestrel-releasing IUD after surgery for symptomatic endometriosis has been demonstrated effective in reducing dysmenorrhea recurrence.(125,126) The effect on deep dyspareunia is less definite and probably limited.”
Use of the levonorgestrel intrauterine system in adolescents with endometriosis
Yoost, J., LaJoie, A. S., Hertweck, P., & Loveless, M. (2013) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2012.11.002 · Cited by 33
Guideline No. 345: Primary Dysmenorrhea
Burnett, M. A. (2025) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2025.102840 · Cited by 32
Reviewing the role of progesterone therapy in endometriosis
Karim, A., Shafiee, M. N., Aziz, N. H. A., Omar, M. H., Ghani, N. A. A., Lim, P. S., Zin, R. R. M., & Mokhtar, N. M. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1490404 · Cited by 33
“Besides improvement of pelvic pain [59], anti-proliferative”
Postoperative hormonal therapy after surgical excision of deep endometriosis
Somigliana, E., Busnelli, A., Benaglia, L., Viganò, P., Leonardi, M., Paffoni, A., & Vercellini, P. (2016) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2016.03.030 · Cited by 37
“Evidence suggests a beneficial effect on the prevention of dysmenorrhea recurrence [37,39] but, given its main local action, evidence is required to evaluate its efficacy in the prevention of endometriomas and other pain symptoms.”
BackgroundYucel, N., Baskent, E., Karamustafaoglu Balci, B., & Goynumer, G. (2018) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12773 · Cited by 30
Contraception and endometriosis: challenges, efficacy, and therapeutic importance
Fraser, I. S., & Weisberg, E. (2015) · Open Access Journal of Contraception · doi:10.2147/oajc.s56400 · Cited by 36
Endometriosis for the primary care physician
Youngster, M., Laufer, M. R., & DiVasta, A. D. (2013) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e3283628092 · Cited by 35
Song, S. Y., Park, M., Lee, G. W., Lee, K. H., Chang, H. K., Kwak, S. M., & Yoo, H. J. (2018) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2018.10.014 · Cited by 24
Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial
Tanmahasamut, P., Saejong, R., Rattanachaiyanont, M., Angsuwathana, S., Techatraisak, K., & Sa‐nga‐areekul, N. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1296124 · Cited by 27
“Although conservative surgery is effective in treatment of endometriosis-related pain, hormonal treatment is needed to further treat and prevent recurrence of disease [14].”
BackgroundSelf-citationSchwartz, B. I., Alexander, M., & Breech, L. L. (2020) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2020.05.041 · Cited by 23
Cassani, C., Tedeschi, S., Cucinella, L., Morteo, V., Camnasio, C. A., Tiranini, L., Martini, E., & Nappi, R. E. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108129 · Cited by 27
Zheng, Y., Ma, R., Xu, H., Wang, L., Zhang, L., Mao, H., & Zhao, R. (2023) · Medicine · doi:10.1097/md.0000000000034496 · Cited by 19
“075mg, qd, po for 6 mo 6 mo I–IV 24 PBO Tanmahut, 2012([18]) 54 32.”
Wang, J., Deng, K., Li, L., Dai, Y., & Sun, X. (2022) · Frontiers in Global Women s Health · doi:10.3389/fgwh.2022.1013921 · Cited by 20
Surgical Considerations in the Management of Adolescent Endometriosis—An Expert Commentary
Tyson, N. A., Shim, J. Y., Lee, T., King, C. R., Einarsson, J. I., Hornstein, M. D., & Laufer, M. R. (2024) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2024.01.021 · Cited by 18
Endometriosis — insights into a multifaceted entity
Amălinei, C., Păvăleanu, I., Lozneanu, L., Balan, R. A., Giuşcă, S. E., & Căruntu, I.-D. (2018) · Folia Histochemica et Cytobiologica · doi:10.5603/fhc.a2018.0013 · Cited by 19
Endometriosis: An Update on Management
Bernardi, L. A., & Pavone, M. E. (2013) · Women s Health · doi:10.2217/whe.13.24 · Cited by 16
Traitements médicaux des tumeurs ovariennes présumées bénignes
Thomin, A., Daraï, É., & Chabbert‐Buffet, N. (2013) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/j.jgyn.2013.09.032 · Cited by 17
“[72] Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, Techatraisak K, Indhavivadhana S, Leerasiri P.”
BackgroundAcién, P., Velasco, I., & Acién, M. (2021) · BMC Women s Health · doi:10.1186/s12905-021-01347-9 · Cited by 17
“Subsequently, other studies [9,23-30] have also shown that LNG-IUD is an effective and well accepted treatment to reduce dyspareunia and dysmenorrhea and increase quality of life in women with suspected endometriosis.”
ResultEkin, M., Kaya, C., Erdoğan, Ş. V., Bahçeci, E., Baghaki, H. S., & Yaşar, L. (2020) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2020.1755628 · Cited by 15
“There was only an 11% difference (49% in the Adept group vs. 38% in the control group which lactated Ringer’s solution was used.) in terms of clinical success, which was basically considered as the reduction in adhesions (Tanmahasamut et al. 2012).”
BackgroundRosenberger, D. C., Mennicken, E., Schmieg, I., Medkour, T., Péchard, M., Sachau, J., Fuchtmann, F., Birch, J. V., Schnabel, K., Vincent, K., et al. (2024) · Pain · doi:10.1097/j.pain.0000000000003290 · Cited by 17
Kim, H. Y., Song, S. Y., Jung, S. H., Song, H. J., Lee, M., Lee, K. H., Jung, Y. W., & Yoo, H. J. (2022) · Medicine · doi:10.1097/md.0000000000029023 · Cited by 15
“Many clinical studies have demonstrated the efficacy of LNG-IUS as a first-line treatment([5,10]) and a maintenance therapy after surgical treatment in endometriosis patients.([11,12]) However,”
BackgroundProgesterone receptor ligands for the treatment of endometriosis
Clemenza, S., Capezzuoli, T., Eren, E., GARCIA, J. M. G., Vannuccini, S., & Petraglia, F. (2022) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.22.05157-0 · Cited by 13
Kim, M., Cho, Y. J., Kim, M. K., Jung, Y. W., Yun, B. S., & Seong, S. J. (2016) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2016.03.017 · Cited by 11
“Although the LNG-IUS effectively reduces pain associated with endometriosis [10,11], its efficacy in preventing recurrence of ovarian endometrioma is not proven.”
BackgroundPharmacologic treatment of the ovarian endometrioma
Benagiano, G., Guo, S., Bianchi, P., Puttemans, P., Gordts, S., Petraglia, F., & Brosens, I. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1229305 · Cited by 9
“[49] investigated 55 patients with endometriosis and moderate-to-severe dysmenorrhea undergoing laparoscopic conservative surgery.”
BackgroundAllen, C. L., Banerjee, S., Karoshi, M., Humaidan, P., & Tahmasebi, F. (2025) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-025-07957-0 · Cited by 9
“A 2012 study [47] conducted in Thailand compared the efficacy of the LNG-IUS to expectant management in reducing dysmenorrhoea, non-cyclic pelvic pain and dysparaeunia associated with endometriosis after 12 months.”
Perioperative hormone treatment of endometriosis
Farkas, W., Lazaridis, A., Odejinmi, F., & Hirsch, M. (2023) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000902 · Cited by 8
“Other studies have inferred benefit, either when given individually or in combination with other hormonal treatments [26,27].”
BackgroundGeoffron, S., Cohen, J., Sauvan, M., Legendre, G., Wattier, J., Daraï, É., Fernandez, H., & Chabbert‐Buffet, N. (2018) · Gynécologie Obstétrique Fertilité & Sénologie · doi:10.1016/j.gofs.2018.02.011 · Cited by 11
Geoffron, S., Legendre, G., Daraï, É., & Chabbert‐Buffet, N. (2017) · La Presse Médicale · doi:10.1016/j.lpm.2017.10.005 · Cited by 7
Shirafkan, H., Moher, D., & Mirabi, P. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302108 · Cited by 8
Chinese Obstetrics & Gynecology journal club: a randomised controlled trial
Tsui, I. K., Dodson, W. C., Kunselman, A. R., Kuang, H., Han, F., Legro, R. S., & Wu, X.-K. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010178 · Cited by 6
Gniadek, M., Porubenska, A., Pełka, K., Rzepkowska, Z., & Florjański, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114297 · Cited by 5
“In women not seeking conception, postoperative hormonal therapy may reduce recurrence risk and improve long-term symptom control [94–96].”
N° 345-Directive clinique de consensus sur la dysménorrhée primaire
Burnett, M. A., & Lemyre, M. (2017) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2017.04.006 · Cited by 10
Cost Estimates Associated with Diagnosis and Treatment of Endometriosis
Sivajohan, B., Lin, T., & Bedaiwy, M. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-97236-3_28 · Cited by 5
Shi, J., Zhu, S., Li, X., Dai, Y., & Leng, J. (2023) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2023.102572 · Cited by 6
Contraceptive Devices for Women: Implants, Intrauterine Devices and Other Products
Craik, J., & Rowlands, S. (2014) · Springer eBooks · doi:10.1007/978-3-319-12406-3_8 · Cited by 5
Evans, J. R., Bergus, K. C., Asti, L., Breech, L. L., Cen, R., Gong, Y., Hertweck, S. P., Hoefgen, H. R., Horne, A. H., Lawson, A. A., et al. (2025) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2025.07.010 · Cited by 5
Xiong, Y., Huang, W., Wang, C., Ma, W., Jin, S., Lin, J., Deng, X., Peng, Y., Huang, Y., Du, X., et al. (2025) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.70016 · Cited by 4
Modern views on endometriosis surgery. Literature review
Chernyak, M. M., & Korchynska, O. O. (2021) · Reproductive Endocrinology · doi:10.18370/2309-4117.2021.58.45-52 · Cited by 5
Sun, R., Xu, H., Ma, R., Xu, J., Liu, Y. H., & Mao, D. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1792793 · Cited by 5
Medikamentöse und operative Therapieoptionen
Alkatout, İ., Schollmeyer, T., Doniec, M., Egberts, J., Jonat, W., & Mettler, L. (2013) · gynäkologie + geburtshilfe · doi:10.1007/s15013-013-0018-z · Cited by 3
Non-contraceptive Benefits of Hormonal Methods
Seracchioli, R., Forno, S. D., & Esposti, E. D. (2021) · Trends in andrology and sexual medicine · doi:10.1007/978-3-030-70932-7_10 · Cited by 3
Ogle, K., & Handy, A. B. (2023) · International Journal of Sexual Health · doi:10.1080/19317611.2022.2155898 · Cited by 3
“It is also possible that LNG-IUDs improve sexual function via decreases in symptoms of gynecologic disorders, such as endometriosis (Tanmahasamut et al., 2012).”
BackgroundResearch Progress on the Treatment of Endometriosis with Traditional Chinese and Western Medicine
朱, 姗. (2018) · Advances in Clinical Medicine · doi:10.12677/acm.2018.81014 · Cited by 1
New frontiers in female contraception (and male condoms): 2012
Nelson, A. L. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.679342 · Cited by 1
“The LNG-IUS has been shown to be effective and well accepted for longterm therapy after conservative surgery for women with moderate-to-severe pain related to endometriosis [58].”
BackgroundProgestogens and Endometriosis
Carp, H., Soriano, D., & Zolti, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-14385-9_9 · Cited by 1
Investigational Medical Therapies for Endometriosis: Current Data and Future Trends
Zhang, R., Lebovic, D. I., & Kavoussi, S. K. (2017) · Seminars in Reproductive Medicine · doi:10.1055/s-0037-1604095 · Cited by 1
Progestogens and Endometriosis
Zolti, M., & Carp, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-52508-8_9 · Cited by 1
Houston, B. L., Al-Inany, H. G., Farquhar, C. M., & Abou-Setta, A. M. (2013) · Evidence Based Women s Health Journal · doi:10.1097/01.ebx.0000427509.23062.24 · Cited by 1
Endometriosis en adolescentes: un desafío terapéutico
Constanza Ralph, T., & Carrasco, O. (2014) · Contacto Científico
L'endométriose de l'adolescente Endometriosis by adolescence
Brichant, G., Tebache, L., Pinzauti, S., & Nisolle, M. (2013)
Rebar, R. W. (2012) · Journal watch · doi:10.1056/wh201203080000006
Sacha, C. R., Farland, L. V., Missmer, S. A., & Anchan, R. M. (2017) · Journal of Endometriosis and Pelvic Pain Disorders · doi:10.5301/jeppd.5000305
“Studies have suggested that the LNG-IUD is associated with decreased dysmenorrhea postoperatively in some women, and may treat undiagnosed underlying adenomyosis (4, 9, 15, 16).”
BackgroundLong-acting reversible contraception in adolescents
Vo, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818872-9.00006-6
Chavda, A. S., & Scott, K. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-39982-5_11
Tonelli, G. B. T., Rodrigues, W. C., da Silva, J. E., Juncal, A. M. S., Silveira, J. M., Mendes, G. L., Marchioro, R. M., & Soares, J. M. D. D. S. (2022) · Brazilian Journal of Health Review · doi:10.34119/bjhrv5n2-007
Wu, C. Z., Klebanoff, J. S., & Moawad, G. (2020) · Wiley eBooks · doi:10.1002/9781119482598.ch34
Metadata
- Authors
- Tanmahasamut, P., Rattanachaiyanont, M., Angsuwathana, S., Techatraisak, K., Indhavivadhana, S., & Leerasiri, P.
- Affiliations
- Siriraj Hospital (TH)
- ORCID
- Venue
- Obstetrics & Gynecology
- Published
- 2012-03
- Volume
- 119
- Issue
- 3
- Pages
- 519-526
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W2022191811
- Cited by
- 105
- References
- 30
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 9 · 2020: 7 · 2019: 4 · 2018: 11 · 2017: 13 · 2016: 8 · 2015: 8 · 2014: 4 · 2013: 13 · 2012: 4
- FWCI
- 10.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Obstetrics and Gynecology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Keywords
- levonorgestrel-releasing intrauterine system, pelvic endometriosis, dysmenorrhea, postoperative pain management, laparoscopic conservative surgery, expectant management, dyspareunia, quality of life, long-term hormonal therapy
- MeSH terms
- Adult, Contraceptive Agents, Female, Double-Blind Method, Dysmenorrhea, Endometriosis, Female, Humans, Intrauterine Devices, Medicated, Laparoscopy, Quality of Life, Severity of Illness Index, Levonorgestrel, Pelvic Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.